Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Laurie Carr

Concepts (113)

Concepts are derived automatically from a person's publications.

Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Lung Neoplasms
10
2021
2675
1.290
Why?
Neuroendocrine Cells
2
2016
34
0.900
Why?
Pulmonary Disease, Chronic Obstructive
2
2018
928
0.640
Why?
Carcinoma, Non-Small-Cell Lung
4
2016
1195
0.500
Why?
Lung Diseases, Obstructive
1
2016
43
0.470
Why?
Research Report
1
2016
89
0.440
Why?
Antineoplastic Agents
3
2013
2219
0.380
Why?
Octreotide
1
2013
23
0.380
Why?
Medical Oncology
1
2016
345
0.370
Why?
Early Detection of Cancer
1
2018
506
0.360
Why?
Quinazolines
1
2013
267
0.350
Why?
Lung Diseases
2
2016
787
0.340
Why?
Sirolimus
1
2013
282
0.340
Why?
Neuroendocrine Tumors
1
2013
122
0.330
Why?
Iodine
1
2010
26
0.320
Why?
Pyrazoles
1
2013
517
0.300
Why?
Pyrroles
1
2010
222
0.290
Why?
Pyridines
1
2013
610
0.290
Why?
Delivery of Health Care
1
2016
947
0.280
Why?
Carcinoma
1
2010
225
0.280
Why?
Lung
4
2021
4122
0.270
Why?
Immunosuppressive Agents
1
2013
829
0.270
Why?
Loss of Heterozygosity
1
2007
51
0.260
Why?
Electronic Health Records
1
2016
1210
0.250
Why?
Indoles
1
2010
511
0.240
Why?
Thyroid Neoplasms
1
2010
380
0.230
Why?
Forced Expiratory Volume
2
2018
451
0.220
Why?
Hyperplasia
2
2016
164
0.220
Why?
Tomography, X-Ray Computed
3
2019
2786
0.180
Why?
Solitary Pulmonary Nodule
1
2021
25
0.160
Why?
Drug Resistance, Neoplasm
2
2019
893
0.150
Why?
Proto-Oncogene Proteins c-yes
1
2019
3
0.150
Why?
Dasatinib
1
2019
58
0.150
Why?
Disease Progression
2
2018
2867
0.140
Why?
Humans
15
2021
146342
0.130
Why?
Spirometry
1
2018
234
0.130
Why?
Vital Capacity
1
2018
293
0.120
Why?
Aging
1
2007
1996
0.120
Why?
Pleural Effusion, Malignant
1
2016
12
0.120
Why?
Pleural Neoplasms
1
2016
31
0.120
Why?
Peritoneal Neoplasms
1
2016
103
0.110
Why?
Multiple Pulmonary Nodules
1
2015
23
0.110
Why?
Image Processing, Computer-Assisted
1
2019
778
0.110
Why?
Neoplasm Staging
3
2016
1488
0.100
Why?
Bronchiolitis
1
2015
88
0.100
Why?
Erlotinib Hydrochloride
1
2013
71
0.100
Why?
Machine Learning
1
2019
594
0.100
Why?
Survival Rate
1
2018
2092
0.090
Why?
Biopsy
1
2016
1075
0.090
Why?
Everolimus
1
2013
112
0.090
Why?
Drug Administration Schedule
2
2012
790
0.090
Why?
Follow-Up Studies
2
2021
5439
0.090
Why?
Tomography, Spiral Computed
1
2011
30
0.090
Why?
Epidermal Growth Factor
1
2011
157
0.080
Why?
Biopsy, Needle
1
2011
183
0.080
Why?
Registries
2
2021
2400
0.080
Why?
Incidence
1
2018
2936
0.080
Why?
Drug Therapy, Combination
1
2013
1036
0.080
Why?
Carcinoma, Medullary
1
2010
16
0.080
Why?
Tomography, Emission-Computed
1
2010
71
0.080
Why?
Molecular Targeted Therapy
1
2013
447
0.080
Why?
Bronchoscopy
1
2011
227
0.080
Why?
Case-Control Studies
1
2018
3647
0.080
Why?
Chronic Disease
1
2016
1827
0.080
Why?
Aged, 80 and over
3
2018
8391
0.080
Why?
Fluorodeoxyglucose F18
1
2010
164
0.070
Why?
Aged
5
2021
26432
0.070
Why?
Treatment Failure
1
2010
361
0.070
Why?
Communication
1
2016
980
0.070
Why?
Female
7
2019
79499
0.070
Why?
Positron-Emission Tomography
1
2010
343
0.070
Why?
Global Health
1
2011
403
0.070
Why?
Biomarkers
1
2019
4340
0.070
Why?
Neoplasm Metastasis
1
2010
693
0.070
Why?
Occupational Exposure
1
2011
356
0.070
Why?
Cell Proliferation
1
2015
2502
0.060
Why?
United States
2
2018
16136
0.060
Why?
Time Factors
1
2018
7109
0.060
Why?
Comorbidity
1
2011
1665
0.060
Why?
Middle Aged
4
2019
36619
0.060
Why?
Male
6
2019
73396
0.060
Why?
DNA Repair
1
2007
255
0.060
Why?
Cellular Senescence
1
2007
225
0.050
Why?
DNA Damage
1
2007
439
0.050
Why?
Mutation
2
2016
4093
0.050
Why?
Adult
4
2019
41087
0.050
Why?
Risk Factors
1
2018
10921
0.050
Why?
Cell Differentiation
1
2010
1982
0.050
Why?
Antineoplastic Combined Chemotherapy Protocols
1
2012
1998
0.050
Why?
Infant
1
2016
10114
0.040
Why?
Patient Identification Systems
1
2021
16
0.040
Why?
Incidental Findings
1
2021
81
0.040
Why?
Retrospective Studies
2
2016
17438
0.040
Why?
Reference Standards
1
2019
176
0.040
Why?
Oncogenes
1
2016
113
0.030
Why?
Diagnosis, Differential
1
2019
1503
0.030
Why?
Disease-Free Survival
1
2016
778
0.030
Why?
Receptors, Platelet-Derived Growth Factor
1
2012
14
0.020
Why?
Proto-Oncogene Proteins c-sis
1
2012
38
0.020
Why?
Imatinib Mesylate
1
2012
77
0.020
Why?
Neutropenia
1
2012
153
0.020
Why?
Remission Induction
1
2012
308
0.020
Why?
Frail Elderly
1
2012
141
0.020
Why?
Benzamides
1
2012
226
0.020
Why?
Paclitaxel
1
2012
260
0.020
Why?
Fatigue
1
2012
363
0.020
Why?
Piperazines
1
2012
368
0.020
Why?
Survival Analysis
1
2012
1378
0.020
Why?
Pyrimidines
1
2012
532
0.020
Why?
Dose-Response Relationship, Drug
1
2012
2022
0.020
Why?
Animals
1
2007
38107
0.010
Why?
Signal Transduction
1
2012
5246
0.010
Why?
Treatment Outcome
1
2012
11821
0.010
Why?
Carr's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
_
Co-Authors Expand Description
_
Similar People Expand Description
_
Same Department Expand Description
Physical Neighbors Expand Description
_

Copyright © 2026 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)